Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,466 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00005803 | Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma | completed | Phase 1 / Phase 2 | 76 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT00036738 | Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib | completed | Phase 2 | 28 | Fred Hutchinson Cancer Center |
| 1 |
| Jan 29, 2020 |
| clinicaltrials |
| NCT00040846 | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies | completed | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT01484275 | A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma | completed | Phase 2 | 85 | Janssen Research & Development, LLCINDUSTRY | 11 | Jan 27, 2020 | clinicaltrials |
| NCT00558675 | A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy | completed | Phase 1 / Phase 2 | 6 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT00793572 | Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma | completed | Phase 2 | 32 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT01614821 | Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia | completed | Phase 2 | 63 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 21, 2020 | clinicaltrials |
| NCT00048412 | Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H | completed | Phase 1 / Phase 2 | 40 | Baylor College of MedicineOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT00651937 | Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden | completed | Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT00490529 | Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL | completed | Phase 2 | 59 | Ronald LevyOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT02340936 | Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma | completed | Phase 1 / Phase 2 | 53 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT00481871 | Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies | completed | Phase 1 / Phase 2 | 119 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 7, 2020 | clinicaltrials |
| NCT01851551 | Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL | completed | Phase 1 / Phase 2 | 22 | Acrotech Biopharma Inc.INDUSTRY | 2 | Jan 3, 2020 | clinicaltrials |
| NCT01527045 | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 47 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT00980395 | Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma(VCR) | completed | Phase 2 | 24 | University of ArizonaOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT00723099 | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | completed | Phase 2 | 73 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT01576588 | Rituximab in Pretreated Elderly or Unfit B-CLL Patients | completed | Phase 2 | 25 | Prof. Dr. Med. Laimonas GriskeviciusOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT00027820 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | Phase 1 / Phase 2 | 106 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 20, 2019 | clinicaltrials |
| NCT00001637 | Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults | completed | Phase 2 | 28 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00581776 | Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma | completed | Phase 2 | 30 | University of Wisconsin, MadisonOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00925782 | PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation | completed | Phase 2 | 24 | Acrotech Biopharma Inc.INDUSTRY | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00450814 | Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 48 | Mayo ClinicOTHER | 1 | Dec 16, 2019 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT00581854 | Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma | completed | Phase 2 | 22 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT00581919 | Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma | completed | Phase 2 | 32 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT02410694 | Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 2 | 90 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 3 | Dec 13, 2019 | clinicaltrials |
| NCT02057640 | MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma | completed | Phase 1 / Phase 2 | 16 | Jason ValentOTHER | 1 | Dec 11, 2019 | clinicaltrials |
| NCT01251575 | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | completed | Phase 2 | 77 | Fred Hutchinson Cancer CenterOTHER | 2 | Dec 9, 2019 | clinicaltrials |
| NCT00185692 | Allogeneic Transplantation From Related Haploidentical Donors | completed | Phase 2 | 16 | Stanford UniversityOTHER | 1 | Dec 4, 2019 | clinicaltrials |
| NCT00992992 | Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma | completed | Phase 2 | 25 | GlaxoSmithKlineINDUSTRY | 0 | Dec 4, 2019 | clinicaltrials |
| NCT00866138 | Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3 | completed | Phase 2 | 24 | AB ScienceINDUSTRY | 1 | Dec 3, 2019 | clinicaltrials |
| NCT01352286 | Redirected Auto T Cells for Advanced Myeloma | completed | Phase 2 | 25 | GlaxoSmithKlineINDUSTRY | 1 | Dec 3, 2019 | clinicaltrials |
| NCT00974233 | Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL | completed | Phase 2 | 34 | University of Wisconsin, MadisonOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT02254772 | A Phase I/II Study of Intratumoral Injection of SD-101 | completed | Phase 1 / Phase 2 | 9 | Robert LowskyOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT01197560 | Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 2 / Phase 3 | 111 | CelgeneINDUSTRY | 9 | Nov 25, 2019 | clinicaltrials |
| NCT01523834 | Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT(FIL_PanAL10) | completed | Phase 2 | 35 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Nov 22, 2019 | clinicaltrials |
| NCT00401843 | A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 307 | Janssen Research & Development, LLCINDUSTRY | 18 | Nov 19, 2019 | clinicaltrials |
| NCT02290431 | Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 31 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 18, 2019 | clinicaltrials |
| NCT00445692 | Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma | completed | Phase 2 | 32 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT00044018 | CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 102 | CelgeneINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT00065351 | Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 222 | CelgeneINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT00105001 | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 210 | Fred Hutchinson Cancer CenterOTHER | 3 | Oct 30, 2019 | clinicaltrials |
| NCT01939899 | Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma | completed | Phase 2 | 29 | Millennium Pharmaceuticals, Inc.INDUSTRY | 4 | Oct 29, 2019 | clinicaltrials |
| NCT02530515 | Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2019 | clinicaltrials |
| NCT01392079 | Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine | completed | Phase 2 | 135 | University of UlmOTHER | 3 | Oct 24, 2019 | clinicaltrials |
| NCT01142232 | Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma | completed | Phase 1 / Phase 2 | 60 | Attaya SuvannasankhaOTHER | 1 | Oct 22, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Jan 29, 2020source: clinicaltrials